A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2018
At a glance
- Drugs Capmatinib (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 30 May 2018 The study has been completed in Netherlands.
- 29 Jul 2017 Planned End Date changed from 1 Mar 2018 to 30 Mar 2018.
- 29 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 30 Jan 2018.